Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00340457 · ClinicalTrials.gov registry record
Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States
A clinical trial of Renal Cell Carcinoma and Kidney Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 2,424
- Enrollment target
- 2
- Study locations
NCT00340457 is a study of Renal Cell Carcinoma and Kidney Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,424 participants, above the 223-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (987% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT00340457, a study of Renal Cell Carcinoma and Kidney Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 2,424 participants
- Enrollment target
- 2
- Study locations
Study Summary
Incidence rates of renal cell cancer have increased rapidly in the U.S. and other countries. In particular, rates among African Americans have risen more sharply than any other cancer site. We propose to conduct a population-based case-control study of renal cell cancer in areas of the U.S. with a high proportion of African American residents. We will include two study centers and one data coordinating center and will recruit study participants over a period of four years. We plan to conduct in-person interviews with 2,100 cases (1,400 whites and 700 blacks) and 2,800 controls (1,400 each of whites and blacks) to elicit information on demographic background and history of exposures. A 40 ml blood sample will be collected from living cases and controls to measure certain environmental exposures and for genetic analyses. Two buccal cell samples will be collected from living cases and controls for genetic analyses. Tumor tissue blocks will be collected from as many cases as possible for assays of tumor mutations. Diagnostic slides will be collected for standardized reclassification of tumors into clear cell, papillary, and other histologic subtypes. Medical records for all cases will be reviewed for health insurance coverage, concomitant conditions, presenting symptoms, tumor stage, size and grade, and methods leading to diagnosis of renal cell cancer.
Conditions Studied
Study Locations (2)
Illinois
- University of Illinois at Chicago - Chicago
Michigan
- Wayne State University - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,424 participants |
| Start Date | 2001-11-16 |
| Est. Completion | 2016-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00340457
The ClinicalTrials.gov registry entry for NCT00340457 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,424 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 223-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (987% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT00340457 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT00340457 about?
NCT00340457 is a clinical study titled "Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States". Incidence rates of renal cell cancer have increased rapidly in the U.S. and other countries. In particular, rates among African Americans have risen more sharply than any other cancer site. We propose to conduct a population-based case-control study of renal cell cancer in areas of the U.S. with a h...
What is the current status of trial NCT00340457?
This trial is currently completed. The enrollment target is 2,424 participants. The study started on 2001-11-16. Estimated completion is 2016-01-01.
What conditions does trial NCT00340457 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Kidney Cancer.
Who is sponsoring clinical trial NCT00340457?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00340457 being conducted?
This trial has 2 study locations across Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
PET/MR for Characterization of Renal Masses (RMs)
RECRUITING
-
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
RECRUITING
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.